Ranbaxy Agrees To Pay $500 Million To Resolve Manufacturing Violations At Indian Sites
This article was originally published in PharmAsia News
Executive Summary
In the final stage of a drawn-out saga, Ranbaxy will pay $500 million to U.S. federal agencies to settle civil and criminal proceedings related to manufacture and supply of adulterated drugs from two Indian sites.